Documents | Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance | NICE

Documents

A list of downloadable documents created during development.

Background information

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: review decision - April 2015 information
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: appendix A - GE decision paper - April 2015 ^{PDF 120.27 KB} 27 April 2015
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: review proposal - April 2014 information
Appendix A - provisional matrix of stakeholders ^{PDF 97.94 KB} 23 April 2014
Appendix B - proposal paper presented to the Institute's Guidance Executive ^{PDF 873.38 KB} 23 April 2014
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: press release information
2011/047 NICE guidance extends recommendations on Alzheimer's drugs ^{PDF 89.17 KB} 06 December 2013

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): EIA form for guidance development

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): EIA form for guidance development ^{PDF 74.21 KB} 29 March 2011

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation document information
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): evaluation report
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): a systematic review and economic model A ^{PDF 4.31 MB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): a systematic review and economic model B ^{PDF 2.18 MB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): additional analysis for PenTAG ^{PDF 34.83 KB} 07 January 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): PenTAG new results ^{PDF 1.29 MB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): PenTAGs parameters in the Lundbeck model ^{PDF 49.79 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): consultee and commentator comments on the assessment report
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from the Research Institute for the Care of Older People ^{PDF 80.82 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Shire ^{PDF 84.85 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Novartis ^{PDF 103.64 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from NHS Quality Improvement Scotland ^{PDF 129.12 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from NHS West Kent ^{PDF 67.89 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): commments from the Alzheimer's Society ^{PDF 172.59 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Eisai Ltd/Pfizer Ltd (joint response) ^{PDF 583.29 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Lundbeck ^{PDF 872.83 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): non-manufacturer submission
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Alzheimer's Society (part 1) ^{PDF 371.99 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): British Geriatrics Society ^{PDF 159.99 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Royal College of Psychiatrists ^{PDF 211.75 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): manufacturer full submissions
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Eisai Ltd/Pfizer Ltd (joint submission) ^{PDF 924.29 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Lundbeck UK ^{PDF 998.77 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Shire Pharmaceuticals ^{PDF 134.41 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): response from Peninsula Technology Assessment Group (PenTAG) ^{PDF 290.42 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): expert written personal statements
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Connelly ^{PDF 123.32 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Hill ^{PDF 53.62 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Simmons ^{PDF 62.23 KB} 07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): overview ^{PDF 611.9 KB} 07 October 2010

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report (part 1) ^{PDF 4.31 MB} 14 July 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report (part 2) ^{PDF 2.15 MB} 14 July 2010

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final protocol

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final protocol ^{PDF 111.79 KB} 20 January 2010

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final matrix

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final matrix ^{PDF 30.36 KB} 07 December 2009

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final scope

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final scope ^{PDF 45.87 KB} 20 November 2009

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the provisional matrix

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the provisional matrix ^{PDF 29.81 KB} 20 November 2009

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the draft scope

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the draft scope ^{PDF 231.5 KB} 20 November 2009

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): provisional matrix

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): provisional matrix ^{PDF 29.98 KB} 24 September 2009

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): draft scope

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): draft scope ^{PDF 50.32 KB} 24 September 2009